Treatment Guidelines for Alzheimer's Disease

Disease Severity and Treatment Choice

The American College of Physicians recommends considering memantine for patients with moderate to severe Alzheimer's disease, as it may improve quality of life 2
Cholinesterase inhibitors (donepezil, galantamine, or rivastigmine) are the first-line agents for patients with mild to moderate Alzheimer's disease 3, 4, 5, 6

For mild to moderate AD: Start with a cholinesterase inhibitor as monotherapy 3, 4, 5
For moderate to severe AD: Either start memantine as monotherapy 1, 2 or use combination therapy with memantine plus a cholinesterase inhibitor 1
Combination therapy (memantine plus cholinesterase inhibitor) shows superior outcomes compared to cholinesterase inhibitor monotherapy in moderate to severe disease 1

While memantine produces statistically significant improvements in moderate to severe AD, the clinical significance may be modest 6, 2
Effect sizes are generally small but consistent across cognition and global assessment domains 3, 4, 5, 6
Quality of life improvements include less agitation in treatment groups 1

Clinically meaningful worsening of dementia over 6 months without other contributing factors may indicate the need to consider discontinuation 1, 2
No observable clinical benefit during treatment may also indicate the need to consider discontinuation 1, 2
Progression to severe or end-stage dementia with dependence in most basic activities of daily living may indicate the need to consider discontinuation 1, 2
Continue memantine if there has been clinically meaningful reduction in neuropsychiatric symptoms (psychosis, agitation, aggression), even with cognitive and functional decline 1